Bing Han

Title: Innovations in Immunomodulatory Medicines by Bing Han

Introduction

Bing Han is a prominent inventor based in Xi'an, China. He has made significant contributions to the field of immunomodulatory medicines, particularly in the treatment of neuromyelitis optica and immune rejection after skin transplantation. His innovative work focuses on the applications of ellagic acid and its metabolic derivatives.

Latest Patents

Bing Han holds a patent for "Applications of ellagic acid in preparation of immunomodulatory medicines for treatment of neuromyelitis optica or immune rejection after skin transplantation." This patent outlines the use of ellagic acid and a metabolic derivative, urolithin, in developing an immunomodulatory medicine. The research employs classical animal models of autoimmunity and immunoregulation, such as experimental autoimmune encephalomyelitis and neuromyelitis optica mouse models. The experiments demonstrate that ellagic acid and its derivatives significantly improve recovery from experimental autoimmune encephalomyelitis, inhibit inflammatory cell infiltration into the central nervous system, ameliorate experimental colitis severity, and suppress graft rejection.

Career Highlights

Bing Han is affiliated with Shaanxi Normal University, where he conducts his research and development work. His innovative approaches have garnered attention for their potential clinical applications and development prospects. His research has shown promising results in enhancing immune tolerance and improving neurological functions.

Collaborations

Bing Han collaborates with notable colleagues, including Yuan Zhang and Wenhui Qi. Their combined efforts contribute to advancing research in immunomodulatory therapies.

Conclusion

Bing Han's work in the field of immunomodulatory medicines showcases the potential of ellagic acid and its derivatives in treating complex medical conditions. His innovative research continues to pave the way for future advancements in immunotherapy.